Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22278262 | 0.80 | METAP2 (0.35) | SLC6A3SLC6A4IDO1METAP2SLC6A2 | |
| SCHEMBL14337906 | 0.79 | SLC6A3 (0.44) | SLC6A3SLC6A4IDO1ALDH1A1SLC6A2 | |
| Hydrochloric Acid SCHEMBL22265756 | 0.79 | IDO1 (0.34) | SLC6A3SLC6A4IDO1METAP2SLC6A2 | |
| SCHEMBL26081073 | 0.78 | USP2 (0.40) | SLC6A3SLC6A4IDO1METAP2 | |
| SCHEMBL23365228 | 0.72 | METAP2 (0.36) | METAP2 | |
| SCHEMBL1823510 | 0.70 | MAOA (0.50) | SLC6A3SLC6A4IDO1METAP2 | |
| SCHEMBL26081072 | 0.69 | KDM4E (0.49) | SLC6A3SLC6A4IDO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31118261 | 0.68 | SLC6A3 (0.39) | SLC6A3SLC6A4IDO1 | |
| SCHEMBL31118162 | 0.67 | LRRK2 (0.33) | IDO1 | |
| SCHEMBL26081240 | 0.66 | NOS3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | SLC6A3 657/4885SLC6A4 411/4885IDO1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.